Bimodal HIV env DNA+protein immunization generates potent immune responses and protection against SHIV challenge. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Bimodal HIV env DNA+protein immunization generates potent immune responses and protection against SHIV challenge.

Conf Adv AIDS Vaccine Dev. 1997 May 4-7;:59. Unique Identifier : AIDSLINE MED/97927039
Liu MA; Letvin NL; Montefiori DC; Yasotomi Y; Perry HC; Davies ME; Lekutis C; Alroy M; Freed DL; Lord CI; Handt LK; Shiver JW; Merck Research Laboratories, West Point, PA. Fax: (215) 652-7320.

Abstract: DNA vaccines provide an approach for inducing neutralizing antibody and cellular responses for a potential HIV vaccine. We have demonstrated potent, boostable, long-lived HIV-1 envelope Env)-specific CTL responses in rhesus monkeys following immunization with DNA plasmid encoding HIV-1 env. Following boosting with recombinant HIV-1 Env protein, high titer neutralizing antibody was observed in this nonhuman primate species. Moreover, in a pilot study, an HIV-1 HXBc2 env DNA prime/HI-1HXBc2 env DNA + recombinant HIV-1 IIIB Env protein boost vaccination regimen protected monkeys from infection following intravenous challenge with a chimeric virus expressing HIV-1 HXBc2 env on an SIV(mac) backbone (SHIV-HXBc2). The protection was demonstrated by ELISA analysis of SIV p27 Gag antigen following 14 days of in vitro culture of PBMCs recovered from challenged animals, Western blot evaluation of anti-HIV-2 Gag antibodies, and PCR evaluation of SIV gag/pol from DNA from PBMCs. The potent immunity and protection seen in these pilot experiments suggest that a DNA immunization with a DNA + protein boost regiment warrants active investigation as a vaccine strategy to prevent HIV-1 infection.
Keywords: *AIDS Vaccines/IMMUNOLOGY *Genes, env *HIV-1/GENETICS *Vaccines, DNA/IMMUNOLOGYKWDaidsvaccines/immunologyKWDgenes,envKWDhiv-1/geneticsKWDvaccines,dna/immunology
971130
M97B1184

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .